Zlom v léčbě nemocného srdce. Nová terapie výrazně pomáhá, dostupnost ale není ideální

Hypertrophic cardiomyopathy is a rare genetically determined disease in which the heart muscle abnormally thickens, typically manifesting between ages 30 and 50 and affecting more men. For decades, treatment focused only on symptom relief using beta-blockers. In the past three years, a breakthrough occurred with the introduction of the first specific medication directly targeting this condition. Modern therapy has achieved excellent results - 90 percent of patients improved dramatically and experienced improved quality of life. However, treatment is time-consuming and requires a demanding titration phase, cardiographic examinations, and regular parameter monitoring. The main challenge is limited availability of modern therapy, as not all specialized facilities have official center status, making it difficult for patients to access this treatment.